Cybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters?

• Cybin, operating as Helus Pharma, has advanced its lead psychedelic candidate HLP003 into an ongoing Phase 3 trial for adjunctive treatment of major depressive disorder and recently raised about US$50,000,000 in an underwritten public offering to support its development programs.
• This combination of late-stage clinical progress and fresh funding highlights how Cybin is positioning HLP003 within the evolving landscape of interventional psychiatry for depression care.
• We’ll now explore how the Phase 3 progress for HLP003 reshapes Cybin’s existing investment narrative and its longer-term risk profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Cybin Investment Narrative Recap

To own Cybin, you have to believe that HLP003 can successfully clear Phase 3 in major depressive disorder and translate into an accepted clinic based treatment model. The current Phase 3 progress remains the key near term catalyst, while the main risk is still clinical or regulatory setbacks that extend Cybin’s loss making period. The recent US$50,000,000 offering does not change that clinical risk, but it does modestly ease near term funding pressure.

Among recent updates, the US$50,000,008 follow on equity offering on June 24 stands out as most relevant. It gives Cybin additional runway to execute its late stage HLP003 programs while it reports continued net losses of about US$148,000,000 for the year. That added cash supports trial continuity and data readouts, but also reminds shareholders that dilution has been meaningful and may remain a feature as the company pursues its clinical catalysts.

Yet behind this Phase 3 opportunity, investors should also be aware of the risk that prolonged losses and further equity raises could...

Read the full narrative on Cybin (it's free!)

Cybin's narrative projects $174.0 million revenue and $37.4 million earnings by 2029. This requires earnings to improve by about $160.6 million from -$123.2 million today.

Uncover how Cybin's forecasts yield a $49.46 fair value, a 603% upside to its current price.

Exploring Other Perspectives

Some analysts were already cautious, projecting only about US$5,500,000 in revenue and roughly US$1,100,000 in earnings by 2029, so compared with the cleaner execution story around HLP003 these lower estimates reflect a much more pessimistic view that new data and funding could either challenge or reinforce over time.

Explore 7 other fair value estimates on Cybin - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cybin research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Cybin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cybin's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com